Document:

EX-10.19

 Exhibit 10.19 
  

 
 Deed of Indemnity, Insurance and Access 
  

	(1)	Nexvet Biopharma public limited company 

  

	(2)	[Director or Officer name] 

 THIS DEED is made on [Date] 

BETWEEN: 
  

	1.	Nexvet Biopharma public limited company, a company incorporated in Ireland (registered no. 547923), whose registered office is at 88 Harcourt Street, Dublin 2, Ireland (the “Company”); and

  

	2.	[Director or Officer name] of [Address] (the “Officer”). 

 WHEREAS: 

 

	(A)	The Officer is a director of the Company. 

  

	(B)	The Company has agreed, subject always to the prohibitions and limitations imposed by law, to indemnify the Officer in respect of certain liabilities as set out in this Deed and the Officer has agreed to comply with
certain related obligations also as set out in this Deed. 

 IT IS AGREED as follows: 

 

	1.	DEFINITIONS AND INTERPRETATION 

 IN THIS DEED, UNLESS THE CONTEXT OTHERWISE REQUIRES: 

 

	1.1	Definitions 

 The following words bear the meanings assigned to them below: 

“Act” means the Companies Act 1963. 

“Associated Company” means: 
  

	 	(a)	a subsidiary undertaking of the Company from time to time, or 

  

	 	(b)	any undertaking (a) in which the Company or any of its subsidiary undertakings holds any share capital and (b) of which the Officer is a director and in such capacity is a nominee of the Company or any of its
subsidiary undertakings; or 

  

	 	(c)	any undertaking in which the Officer is acting as officer, employee, trustee or agent at the Company’s request. 

“Board Documents” includes all: 
  

	 	(a)	written communications circulated or made available to the Officer by the Company; 

  

	 	(b)	minutes of meetings of the Company and the Board; and 

  

	 	(c)	Documents circulated to the directors of the Company in connection with any meetings or deliberations of the Board. 

“Books” means all the financial, technical and commercial information belonging to the Company from time to time and includes
the Board Documents. 
 “Business Day” means a day other than a Saturday or Sunday on which banks are generally open for
business in Dublin. 

  
 1 

 “Claim” means any claim, action, proceeding, investigation, demand or judgment
made by a person other than the Officer. 
 “Commencement Date” means [Date]. 

“Connected Person” means in relation to a person, any other person: 

 

	 	(a)	who is a connected person for the purposes of section 10 of the Taxes Consolidation Act 1997 to the first mentioned person; and/or 

  

	 	(b)	with whom the first mentioned person is acting in concert (as defined in section 1(13) of the Irish Takeover Panel Act 1997). 

“Information” means all or any part of information contained in or related to the business or a transaction of the Company, a
Book or a discussion at a meeting of the Company. 
 “Permitted Purpose” means 

 

	 	(a)	to discharge the Officer’s duty as a director of the Company; 

  

	 	(b)	in connection with a claim commenced or arising during the Term in which the Officer: 

  

	 	(i)	is subject or is a party (except where claiming against or being claimed against by the Company); 

  

	 	(ii)	is directly involved in (including as a witness); 

  

	 	(iii)	proposes in good faith to bring (except against the Company); or 

  

	 	(iv)	believes on reasonable grounds will be brought against the Company (except by the Company); or 

  

	 	(c)	any other purpose in respect of which the Company gives its written consent. 

“Term” means the period set out in Clause 5. 
  

	1.2	Interpretation 

  

	 	1.2.1	References to a statute or statutory provision include: 

  

	 	(a)	that statute or provision as from time to time modified, re-enacted or consolidated whether before, on or after the date of this Deed; and 

 

	 	(b)	any subordinate legislation made from time to time under that statute or statutory provision. 

  

	 	1.2.2	References to one gender include all genders and references to the singular include the plural and vice versa. 

  

	 	1.2.3	References to a company shall include any company, corporation or any body corporate, wherever incorporated. 

  

	 	1.2.4	The words “holding company”, “undertaking” and “subsidiary undertaking” shall have the same meaning in this Deed as their respective definitions in the Act. 

 

	 	1.2.5	Reference to Clauses are to Clauses of this Deed; 

  
 2 

	 	1.2.6	A conviction, judgment or refusal of relief becomes final: 

  

	 	(a)	if not appealed against, at the end of the period for bringing an appeal; or 

  

	 	(b)	if appealed against, at the time when the appeal (or any further appeal) is determined and the period for bringing any further appeal has ended or if the appeal is abandoned or otherwise ceases to have effect.

  

	 	1.2.7	Headings shall be ignored in interpreting this Deed. 

  

	2.	INDEMNITY 

  

	2.1	Subject to the provisions of this Deed, the Company agrees to indemnify the Officer out of its own funds against any liability incurred by, or attaching to, the Officer on or after the Commencement Date:

  

	 	2.1.1	in connection with any negligence, default, breach of duty or breach of trust by the Officer in relation to the Company or any Associated Company; or 

	 	

	 	2.1.2	in the actual or purported execution and/or discharge of the Officer’s duties and/or the actual or purported exercise of the Officer’s powers and/or otherwise in relation to, or in connection with, the
Officer’s duties, powers or office as an employee, officer, trustee or agent of the Company and/or any Associated Company. 

  

	2.2	This indemnity shall extend to such costs and expenses incurred by the Officer in relation to the matters in respect of which he is indemnified in this Clause 2 in respect of: 

 

	 	2.2.1	Claims based on acts or failures to act in the exercise of the Officer’s duties or any other duties currently or previously performed by the Officer at the Company’s or any Associate Company’s request, in
the actual or purported execution and/or discharge of the Officer’s duties and/or the actual or purported exercise of the Officer’s powers and/or otherwise in relation to, or in connection with, the Officer’s duties, powers or office
as an employee, officer, advisor or agent of the Company and/or any Associated Company; 

	 	

	 	2.2.2	the reasonable costs and expenses of conducting a defence, using counsel of the Officer’s choosing, against any such Claim (including for the avoidance of doubt reasonable fees and expenses of the Officer’s
legal advisers); 

	 	

	 	2.2.3	any damage, fines or other costs payable by the Officer as a result of an act or failure to act as referred to above; and 

	 	

	 	2.2.4	the reasonable costs of appearing in other legal, judicial, administrative or regulatory proceedings in which the Officer is involved as current or former Officer of the Company, with the exception of proceedings
primarily aimed at pursuing such a claim by or on the Officer’s own behalf. 

  

	2.3	The Officer shall take all reasonable steps to mitigate any loss which, in the absence of mitigation, might give rise to a claim or demand under this Deed against the Company. 

 

	2.4	Notwithstanding anything to the contrary herein, the rights of the Officer under this Deed shall only have effect insofar as they are not contrary to or in violation of the laws of Ireland, including section 200 of the
Companies Act 1963. 

  
 3 

	3.	LIMITATIONS ON INDEMNITY 

  

	3.1	Without prejudice to any other rights or remedies which may be available to the Officer, the indemnity granted by the Company to the Officer in Clause 2 shall not extend to any liability (including any costs and
expenses) incurred by, or attaching to, the Officer: 

  

	 	3.1.1	to the Company or any Associated Company; 

	 	

	 	3.1.2	to pay a fine imposed in criminal proceedings; 

	 	

	 	3.1.3	in defending any criminal proceedings in which he is convicted, where such conviction is final; 

	 	

	 	3.1.4	in defending any civil proceedings brought by the Company or an Associated Company in which judgment is given against him, where such judgment is final; or 

	 	

	 	3.1.5	in connection with any application under Section 42(3) or (4) of the Companies (Amendment) Act 1983 (acquisition of shares by innocent nominee) or Section 391 of the Act (general power to grant relief in
case of honest and reasonable conduct), where the court refuses to grant the Officer relief, and such refusal is final. 

  

	3.2	Furthermore, this indemnity shall not apply: 

  

	 	3.2.1	to the extent that it is not permitted by, or consistent with, law or statute from time to time in force, the memorandum and articles of association of the Company or the rules and regulations of any regulatory body;

	 	

	 	3.2.2	to the extent that the Officer is entitled to be indemnified or reimbursed by any directors’ or officers’ liability insurance or any other insurance and the insurer has paid out; 

	 	

	 	3.2.3	where there has been gross negligence, fraud or wilful default by the Officer; nor 

	 	

	 	3.2.4	to the extent the Officer or a Connected Person has improperly derived a personal benefit or profit, whether directly or indirectly, from the matter in respect of which a liability arises. 

 

	4.	FUNDING OF COSTS AND FINANCIAL LOSS 

  

	4.1	Subject to the Officer complying with his obligations under this Deed, the Company: 

  

	 	(a)	subject to any applicable laws, will do such reasonable things as may enable the Officer to avoid incurring cost or financial loss from a liability described in Clause 2; and / or 

 

	 	(b)	shall pay directly (or if necessary reimburse) any such costs and financial loss within 10 Business Days of receipt of the invoices or any other document evidencing the costs or financial loss of the Officer from a
liability described in Clause 2. 

  

	4.2	If the Company chooses to provide funds or do other things as set out in Clause 4.1 then such funds will become repayable by the Officer (on a pro rata basis, as the case may be, in accordance with Clause 4.3), and the
liability of the Company under Clause 4.1 will be discharged (on a pro rata basis, as the case may be, in accordance with Clause 4.3), as follows: 

  
 4 

	 	4.2.1	in the event of the Officer being convicted in the criminal proceedings referred to in Clause 3.1.2 or 3.1.3, the date when the conviction becomes final; 

	 	

	 	4.2.2	in the event of judgment being given against the Officer in the civil proceedings referred to in Clause 3.1.4 or 3.1.5, the date when the judgment becomes final; and 

	 	

	 	4.2.3	in the event of the court refusing to grant the Officer relief on the application, the date when the refusal of relief becomes final. 

 

	4.3	In the event that in the criminal or civil proceedings referred to in Clause 4.2 more than one criminal or civil charge is brought against the Officer and the Officer is convicted or judgment is rendered against him, as
the case may be, in respect of some but not all of the relevant charges, the funds referred to in Clause 4.2 will become repayable and the Company’s liability will be discharged only on a pro rata basis, to be determined by and between the
Company and the Officer in good faith and in accordance with the principles of reasonableness and fairness, on the basis of the contents of the relevant criminal or civil judgment rendered. 

 

	4.4	If an amount is paid under Clause 4.1 and is subsequently found to be for a liability or costs or expenses which are not covered by the indemnities set out in Clause 2 or is the subject of another payment to the Officer
under directors and officers insurance policy, another insurance policy or another indemnity, then, within 28 days after receipt of a written request from the Company, the Officer must repay such monies to the Company. 

 

	4.5	Without prejudice to any rights of the Company, the Company may, with the prior agreement of the Officer, deduct from any money due to the Officer (including remuneration) in connection with his services to the Company
or any Associated Company, any amount which he owes to the Company under this Deed. 

  

	5.	CONTINUATION OF OBLIGATIONS 

  

	    	The obligations of the Company contained in this Deed shall continue during the period in which the Officer is an officer of the Company or of an Associated Company and for a period of seven years thereafter.

  

	6.	NOTIFICATION AND CONDUCT OF CLAIMS 

  

	6.1	The Officer will promptly, and in any event within 10 Business Days of the date on which the Officer becomes aware of a Claim, notify the Company in writing of any Claim which may give rise to a claim or demand by the
Officer against the Company under this Deed setting out as much information as is available to the Officer (including details of the person(s) making the Claim, the circumstances which gave rise to it and an estimate of the amount of the Claim).

  

	6.2	The Company shall be entitled at any time by notice to the Officer to assume sole conduct of all matters relating to any Claim (including the conduct of any counterclaim or related claim against any person) provided
that it shall only settle, compromise or consent to the entry of any judgment with respect to any Claim with the consent of the Officer, such consent not to be unreasonably withheld. 

 

	6.3	The Officer shall do all such things as the Company may reasonably request in order to permit the Company fully to exercise its rights under Clauses 6.2. and 6.3, and in particular shall: 

  
 5 

	 	6.3.1	provide the Company with such information and copies of such documents relating to any Claim as the Company may reasonably request; 

	 	

	 	6.3.2	not, without the prior written consent of the Company, make any admission in relation to any claim, nor settle, compromise or consent to the entry of any judgment (or offer to do so), with respect to any Claim;

	 	

	 	6.3.3	assist the Company as it may require in resisting, defending or settling such Claim; and 

	 	

	 	6.3.4	allow the Company to take such actions which the Company may deem appropriate in relation to any Claim in the name and on behalf of the Officer, including (without prejudice to the Officer’s right to choose counsel
referred to in Clause 2.2.2) appointing and giving instructions to Counsel and any other professional advisers, under the Company’s sole instructions and commencing and taking any step in any proceedings (including making any admission and
lodging any appeal). 

  

	6.4	If the Officer does not comply with his obligations under Clauses 6.1 and/or 6.3 or the Officer and the Company cannot agree on a course of action in accordance with Clause 6.3, the Company may on giving notice to the
Officer require the Officer to assume the sole conduct of defence of the Claim. 

  

	6.5	For the avoidance of doubt, after notice has been given by the Company to the Officer of its election to assume the conduct of matters relating to a Claim in accordance with the provisions of Clause 6.2, or after notice
has been given by the Company to the Officer requiring the Officer to assume the sole conduct of all matters relating to a Claim pursuant to Clause 6.4, the Officer may engage separate legal or other representation and participate in the
defence of a Claim but any expenses incurred by the Officer in relation to such representation or participation will only be borne by the Company 

  

	 	6.5.1	the extent that those expenses are the subject of an Indemnity; and 

	 	

	 	6.5.2	those expenses incurred in circumstances where the Company has refused to authorise representation or participation by lawyers other than lawyers acting also for the Company; and 

	 	

	 	6.5.3	there is a reasonable likelihood that the interests of the Officer and of the Company would conflict if the same lawyers were to act on behalf of both the Officer and the Company. 

 

	7.	DIRECTORS’ AND OFFICERS’ LIABILITY INSURANCE 

  

	    	The Company undertakes that for the duration of the Officer’s appointment as a director of the Company and for a period of seven years after the termination of the Officer’s appointment as a director of the
Company, the Officer shall be covered by the Company’s directors’ and officers’ liability insurance policy pursuant to and subject to the terms of such policy from time to time in force and to the Company’s policy on such
insurance from time to time. The Officer understands and agrees that in the event that a liability arises (regardless of whether the liability is covered under the terms of such policy) and the insurer fails or refuses to provide him with any
benefit under the directors’ and officers’ liability insurance arrangements provided by the Company, the Officer shall have no right of action against the Company specifically from the fact that the insurer fails or refuses to pay (but,
for the avoidance of doubt, this does not affect the indemnity granted to the Officer under this Deed). 

  
 6 

	8.	SUBROGATION 

  

	    	If the Company makes any payment under this Deed, it shall be subrogated to the extent of such payment to any right the Officer may have for recovery of the amounts so paid from any third party. The Officer agrees
to execute all documents required and do all other acts necessary to effect the foregoing provisions and permit the Company to enforce the rights so subrogated. 

  

	9.	INDEMNITIES IN ARTICLES OF ASSOCIATION 

  

	    	The indemnification provided by this Deed shall not be deemed exclusive of any rights to which the Officer may be entitled under the memorandum or articles of association of the Company, any agreement, any vote of
shareholders or of the board of directors of the Company, or otherwise, or under any laws or regulations in effect now or in the future. 

  

	10.	ACCESS TO COMPANY BOOKS 

  

	10.1	Right to access Books 

  

	 	10.1.1	Subject to Clause 10.1.2, during the Term, the Company must, on request, allow the Officer to inspect and take copies (free of charge) of any Books during business hours. 

 

	 	10.1.2	After the Officer ceases to be an officer of the Company, the right of access and copying is limited to: 

  

	 	(a)	Books to which the Director was entitled to have access while an officer of the Company; and 

  

	 	(b)	Information the Director reasonably believes may be relevant to a Permitted Purpose. 

  

	10.2	Obligations of the Company 

  

	    	During the Term, the Company, must use its reasonable efforts to keep: 

  

	 	(a)	all Books safe and secure from damage; and 

  

	 	(b)	a complete set of all Books. 

  

	10.3	Return of Books 

  

	    	After the Officer ceases to be an officer of the Company, the Officer must return any copies of any Books taken: 

  

	 	(a)	while he was an officer of the Company, promptly after ceasing to be an officer of the Company; and 

  

	 	(b)	after he ceased to be an officer of the Company, promptly after they are no longer required for a Permitted Purpose. 

  
 7 

	10.4	Statutory Rights of Access 

  

	    	This Clause 10 does not adversely affect any statutory right of access which the Officer may have to the Books, including without limitation under Section 202(8) Companies Act, 1990. 

 

	10.5	Confidentiality 

  

	 	10.5.1	Without limiting the Officer’s duties as a director of the Company and subject to Clause 10.5.2, during the Term the Officer must: 

 

	 	(a)	keep all Information contained in the Books confidential; 

  

	 	(b)	must not disclose Information to any person; and 

  

	 	(c)	must not use Information other than for a Permitted Purpose. 

  

	 	10.5.2	The obligations in Clause 10.5.1 do not apply to Information if and to the extent that: 

  

	 	(a)	the disclosure or use is required by law, any regulatory body or any recognised stock exchange on which the shares of the Company or any Associated Company are listed; 

 

	 	(b)	the Information is or comes into the public domain (other than as a result of a contravention by the Director of this deed or any other obligation of confidence); 

 

	 	(c)	disclosure of the Information is reasonably necessary for a Permitted Purpose or to obtain legal, financial or taxation advice for the Officer and, in each case, disclosure of the Information: 

 

	 	(i)	is made on a confidential basis; and 

  

	 	(ii)	will not cause the Company’s right to claim legal privilege in regard to any other Information or documents to be waived; 

  

	 	(d)	disclosure of the Information is reasonably necessary for the purposes of the discharge of the duties of the Officer as a director of the Company; or 

 

	 	(e)	the Company has given its prior written consent to the disclosure of the Information. 

  

	 	10.5.3	The provisions of this Clause 10.5 shall continue to apply after the termination of the Officer’s appointment as a director of the Company and/or any Associated Company without limitation in time.

  

	11.	NOTICES 

  

	11.1	Any notice or other communication in connection with this Deed (each, a “Notice”) shall be: 

  

	 	(a)	in writing; 

  

	 	(b)	delivered by hand, fax, pre-paid first class post or courier. 

  

	11.2	A Notice to the Company shall be sent to the following address, or such other person or address as the Company may notify to the Officer from time to time: 

  
 8 

 Address: the Company’s registered office from time to time 

 

			
	 Attention:
	  	[Chief Executive Officer]
		
	 With copy by email to:
	  	[Email Address]

  

	11.3	A Notice to the Officer shall be sent to the Officer at the following address, or such other person or address as the Officer may notify to the Company from time to time: 

 

			
	 Address:
	  	[Director’s or Officer’s Address]
		
	 With copy by email to:
	  	[Director’s or Officer’s Email]

  

	11.4	A Notice shall be effective upon receipt and shall be deemed to have been received: 

  

	 	(a)	60 hours after posting, if delivered by pre-paid first class post; 

  

	 	(b)	at the time of delivery, if delivered by hand or courier; 

  

	 	(c)	at the time of transmission in legible form, if delivered by fax. 

  

	12.	INVALIDITY 

  

	 	12.1.1	If any provision in this Deed shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision is legal,
valid and enforceable and gives effect to the intention of the parties. 

  

	 	12.1.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 12.2.1, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable, be
deemed not to form part of this Deed and the legality, validity and enforceability of the remainder of this Deed shall, subject to any deletion or modification made under Clause 12.2.1, not be affected. 

 

	13.	VARIATION AND WAIVER 

  

	13.1	No variation of this Deed shall be effective unless in writing and signed by or on behalf of each of the parties. 

  

	13.2	No waiver of any of the provisions of this Deed shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

  

	14.	COUNTERPARTS 

  

	    	This Deed may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. 

 

	15.	WHOLE AGREEMENT 

  

	15.1	This Deed contains the whole agreement between the parties relating to the subject matter of this Deed at the date of this Deed to the exclusion of any terms implied by law which may be excluded by contract and
supersedes any previous written or oral agreement between the Company and the Officer in relation to the matters dealt with in this Deed. 

  
 9 

	15.2	The Officer acknowledges that he has not been induced to execute this Deed by any representation, warranty, assurance or undertaking not expressly incorporated into it. 

 

	16.	ASSIGNMENT 

  

	16.1	The Company may at any time assign to an Associated Company the benefit of the whole or any part of its rights under this Deed provided that such assignment shall be expressed to have effect only for so long as the
assignee remains an Associated Company. 

  

	16.2	The Officer may not assign the benefit of all or any part of his rights under this Deed. 

  

	17.	GOVERNING LAW AND SUBMISSION TO JURISDICTION 

  

	17.1	This Deed shall be governed by the laws of Ireland. The parties irrevocably agree that the courts of Ireland are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this
Deed. The Company agrees to reimburse the Officer for any reasonable travelling expenses incurred by him in attending any court hearings in Ireland, upon production of adequate receipts and to the extent that the Officer may not recover such costs
from any other person. The Officer will repay to the Company any money which he subsequently recovers for such costs from any other person. 

  

	17.2	In the event of any change in applicable law, statute or rule which restricts the right of the Company to indemnify a person serving in a capacity referred to in this Deed, such change, to the extent not otherwise
required by such law, statute or rule to be applied to this Deed, shall have no effect on this Deed or the parties’ rights and obligations hereunder. 

  
 10 

 IN WITNESS WHEREOF this Deed has been delivered on the date first stated above. 

Given under the Common Seal of 
 NEXVET BIOPHARMA LIMITED

 which was affixed hereto and 
 this Deed was delivered: 

 

			
	  
	 	  

	Signature of [Director or Officer]	 	Signature of Director/Company Secretary
		
	  
	 	  

	Name of [Director or Officer] (print)	 	Name of Director/Company Secretary (print)

 Date:          

Signed and Delivered as a Deed by 
 [DIRECTOR] in
the presence of: 
  

			
	  
	 	  

	 Signature of Witness
	 	Signature of [Director or Officer]
		
	  
	 	
	 Name of Witness (print)
	 	
		
	  
	 	
	 Address of Witness (print)
	 	
		
	  
	 	
	 Occupation of Witness (print)
	 	

 Date:         
                              

  
 11EX-4.2

 Exhibit 4.2 

SECURITIES SUBJECT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS
OF ANY STATE OR OTHER JURISDICTION, AND NEITHER THE SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND
APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

COMMON STOCK WARRANT 
 TO
PURCHASE COMMON STOCK OF 
 HIGH THROUGHPUT GENOMICS, INC. 

No. W-35 
 This certifies that, for value
received, The Arizona Board of Regents, on behalf of The University of Arizona (“University”) or its registered transferees (“Holder”), is entitled, subject to the terms and conditions set forth herein, at any time
during the Exercise Period (as defined below), but not thereafter, to subscribe for and purchase from High Throughput Genomics, Inc. a Delaware corporation (the “Company”), On Hundred Thousand (100,000) shares of the
Company’s Common Stock (the “Warrant Shares”), which, as of the date hereof, represents Twelve One-Hundredths of One Percent (.12%) of the outstanding capital stock of the Company on a fully-diluted basis. The
term “Warrant” as used herein, shall mean this Warrant and any warrant delivered in substitution or exchange therefor as provided herein. 

1. Term of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part, from time to time
during the term hereof, commencing on the date hereof and ending at 5:00 p.m. Mountain Standard Time on the Ten (10) year anniversary of the date of this Warrant (the “Exercise Period”), after which time
this Warrant shall be void. 
 2. Exercise Price. The exercise price (“Exercise Price”) of the Company’s Common Stock covered
by this Warrant shall be Six Cents US ($0.06) per share. The Exercise Price and the number of Warrant Shares shall be subject to adjustment as provided herein. 

3. Exercise of Warrant. 
 (a) Cash
Exercise. This Warrant may be exercised by Holder by (i) the surrender of this Warrant to the Company at the Company’s address given in Section 11(e) below, with the Notice of Exercise attached hereto as Exhibit A duly executed on
behalf of Holder at the office of the Company (or such other office or agency of the Company as the Company may designate by notice in writing to Holder at the address of Holder appearing on the books of the Company) during the Exercise Period and
(ii) the delivery of payment to the Company, for the account of the Company, by cash, wire transfer of immediately available funds to a bank account specified by the Company, or by certified or bank cashier’s check, of the Exercise Price
for the number of Warrant Shares specified in the Notice of Exercise in lawful money of the United States of America. The Company agrees that such Warrant Shares shall be deemed to be issued to Holder as the record holder of such Warrant Shares as
of the close of business on the date on which this 

 
Warrant is surrendered and payment made for the Warrant Shares in accordance with the provisions hereof, and the person entitled to receive the Warrant Shares issuable upon such exercise shall be
treated for all purposes as the holder of record of such shares as of the close of business on such date. A stock certificate or certificates for the Warrant Shares specified in the Notice of Exercise shall be delivered to Holder as promptly as
practicable, and in any event within ten (10) days, thereafter. If this Warrant is exercised only in part, then the Company shall, at the time of delivery of the stock certificate or certificates, deliver to Holder a new Warrant evidencing the
right to purchase the remaining Warrant Shares, which new Warrant shall be identical to this Warrant in all other respects. Upon Holder’s purchase of all the Warrant Shares, the Company shall physically void the Warrant. 

(b) Net Issue Exercise. Notwithstanding any provision herein to the contrary, if the Fair Market Value (as defined below) of one share
of the Company’s Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant pursuant to Section 3(a) hereof, the Holder may elect to receive shares equal to the value
(as determined below) of this Warrant (or portion thereof being canceled) by surrendering this Warrant to the Company, with a duly executed Notice of Exercise marked to reflect Net Issue Exercise and specifying the number of Warrant Shares to be
purchased, during normal business hours on any business day during the Exercise Period. Such Warrant Shares shall be deemed to be issued to Holder as the record holder of such Warrant Shares as of the close of business on the date on which this
Warrant is surrendered in accordance with the provisions hereof, and the person entitled to receive the Warrant Shares issuable upon such exercise shall be treated for all purposes as the holder of record of such shares as of the close of business
on such date. Upon such exercise, Holder shall be entitled to receive, and the Company shall issue to Holder, a number of Warrant Shares computed as of the date of surrender of this Warrant to the Company using the following formula: 

 

							
		  	X =	  	 Y(A-B) 
  

		  		  	    A
	Where	  	X =	  		  	the number of Warrant Shares to be issued to Holder under this Section 3(b);
				
		  	Y =	  		  	the number of Warrant Shares in respect of which this election is made;
				
		  	A =	  		  	the Fair Market Value (as defined below) of one share of the Company’s Common Stock at the date of such calculation; and
				
		  	B =	  		  	the Exercise Price (as adjusted to the date of the issuance).

 (c) Fair Market Value. For the purposes of Section 3(b) hereof, the fair market value
(“Fair Market Value”) of one share of the Company’s Common Stock shall mean, as of any date: 
 (i) the fair market
value of the shares of the Company’s Common Stock as of such date, as determined from the last closing price per share of the Company’s Common Stock on the principal national securities exchange on which the Company’s Common Stock is
listed or admitted to trading, 

  
 2 

 (ii) the fair market value of the shares of the Company’s Common Stock as of such date, as
determined from the last reported sales price per share of the Company’s Common Stock on the Nasdaq National Market or the Nasdaq Small-Cap Market (collectively, “Nasdaq”) if the Company’s Common Stock is not listed or
traded on any such exchange, 
 (iii) the fair market value of the shares of the Company’s Common Stock as of such date, as determined
from the average of the bid and asked price per share of the Company’s Common Stock as reported in the “pink sheets” published by the National Quotation Bureau, Inc. if the Company’s Common Stock is not listed or traded on any
exchange or Nasdaq, or 
 (iv) if such quotations are not available, the fair market value per share of the Company’s Common Stock on
the date such notice was received by the Company as determined in good faith by the Board of Directors of the Company; provided, however, that if the Warrant is being exercised immediately prior to or upon the closing of an IPO (as defined in
Section 9(e) below), the Fair Market Value shall not be determined by the Board of Directors and shall be the initial “price to public” of one share of the Company’s Common Stock specified in the final prospectus with respect to
the IPO. 
 4. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. In lieu of any fractional share to which Holder otherwise would be entitled, the Company shall make a cash payment equal to the fair market value of one share of the Company’s Common Stock as determined under Section 3(c)
multiplied by such fraction. 
 5. Replacement of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, upon delivery of a certification of loss (without obligation to indemnify) by Holder reasonably satisfactory in form and substance to the Company or, in the
case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount. 

6. No Rights as Stockholder. Except as provided in this Section 6 (Subject to Sections 7 and 11 of this Warrant), the Holder shall not be entitled
to vote or be deemed the holder of Common Stock, nor shall anything contained in this Warrant be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or
upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon recapitalization, issuance of stock, reclassification of stock, change of par value, or change of stock to no par
value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive subscription rights or otherwise until the Warrant shall have been exercised as provided herein. Nothing contained herein shall obligate Holder
to purchase any Company securities (upon exercise of this Warrant or otherwise). 
 7. Adjustments. 

(a) Stock Dividend, Subdivision or Split-Up. If, at any time after the date hereof, the number of shares of the Company’s capital
stock outstanding is increased by a stock dividend or by a subdivision or split-up of shares, then, following the record date for the determination of holders of capital stock entitled to receive such stock dividend, subdivision or split-up, the

  
 3 

 
Exercise Price shall be appropriately decreased and the aggregate number of Warrant Shares shall be increased in proportion to such increase in outstanding shares. The foregoing provisions shall
similarly apply to any successive stock dividend, subdivision or split-up. 
 (b) Combination, Reverse-Split. If, at any time after
the date hereof, the number of shares of the Company’s capital stock outstanding is decreased by a combination or reverse-split of shares, then, following the record date for the determination of holders of capital stock for such combination or
reverse-split, the Exercise Price shall be appropriately increased and the aggregate number of Warrant Shares shall be decreased in proportion to such decrease in outstanding shares. The foregoing provisions shall similarly apply to any successive
combination or reverse-split. 
 (c) Dividends. If, at any time after the date hereof, the holders of the securities as to which
purchase rights under this Warrant exist at the time shall have received, or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without payment therefor, other or additional
stock or other securities or property (including cash) of the Company by way of a dividend, then, and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of the securities receivable upon exercise of
this Warrant, and without payment of any additional consideration therefor, the amount of such other or additional stock or other securities or property (including cash) of the Company that such Holder would hold on the date of such exercise had it
been the holder of record of the securities receivable upon exercise of this Warrant on the date thereof and had thereafter, during the period from the date thereof to and including the date of such event, retained such shares and/or all other
additional stock available to it during such period, all as adjusted pursuant to this Section 7. 
 (d) Reorganization,
Reclassification, Consolidation, Merger or Asset Sale – Non-University Holder. With respect to any Holder other than University, in the event of any capital reorganization of the Company, any reclassification of the stock of the Company
(other than a change in par value or from par value to no par value or from no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), any consolidation or merger of the Company, or any sale of
all or substantially all of the assets of the Company, this Warrant shall after such reorganization, reclassification, consolidation, merger or asset sale be exercisable for the kind and number of shares of stock or other securities, cash or
property of the Company or of the entity resulting from such reorganization, reclassification, consolidation, surviving such merger, or such asset sale to which the Holder would have been entitled if this Warrant had been exercised immediately prior
to the consummation of such reorganization, reclassification, consolidation, merger or asset sale. The foregoing provisions shall similarly apply to any successive reorganization, reclassification, consolidation, merger or asset sale. 

(e) Reorganization, Reclassification, Consolidation, Merger or Asset Sale – University Holder. With respect to University as
Holder of this Warrant, in the event of any capital reorganization of the Company, any reclassification of the stock of the Company (other than a change in par value or from par value to no par value or from no par value to par value or as a result
of a stock dividend or subdivision, split-up or combination of shares), any consolidation or merger of the Company, or any sale of all or substantially all of the assets of the Company, immediately prior to the consummation of such reorganization,
reclassification, consolidation, merger or asset sale, regardless of the consideration provided for in such reorganization, reclassification, consolidation, merger or asset sale (whether it be shares of stock

  
 4 

 
or other securities, debt, cash or property of the Company or of the entity resulting from such reorganization, reclassification, consolidation, surviving such merger, or such asset sale), at
University’s election, the Company shall pay to University, in lieu of University exercising this Warrant, in cash or cash equivalents the aggregate value of the Warrant Shares as if this Warrant had been exercised immediately prior to the
consummation of such reorganization, reclassification, consolidation, merger or asset sale pursuant to Section 3(b), where Fair Market Value is the price per fully-diluted share of Common Stock payable in such transaction. Such payment shall be
made at the closing of the transaction to which it relates. The foregoing provisions shall similarly apply to any successive reorganization, reclassification, consolidation, merger or asset sale. 

(f) Calculations. All calculations under this Section 7 shall be made to the nearest one hundredth (1/100) of a cent or the
nearest one tenth (1/10) of a share, as the case may be. 
 (g) No Impairment. The Company will not, by any voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant to be observed or performed by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Section 7 and in
the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder of this Warrant against impairment. 
 8.
Representations, Warranties and Covenants. The Company represents, warrants and covenants to the Holder that (a) all shares of the Company’s Common Stock which may be issued upon the exercise of this Warrant will be, when issued,
non-assessable, fully paid, and validly issued, with no personal liability attaching to the ownership thereof, and free from all taxes, liens and charges created by the Company with respect to the issue thereof and (b) the issuance of this
Warrant, the shares of the Company’s Common Stock issuable hereunder and the other transactions contemplated hereunder do not require the consent of any person or entity and do not and shall not conflict, result in a default under or violate
the terms of any agreement, contract, document, instrument or obligation which may be binding upon the Company. The Company covenants to the Holder that it will from time to time take all such action as may be required to assure that the stated or
par value per share of the Company’s Common Stock is at all times no greater than the then-effective Exercise Price. The Company further covenants and agrees that it will take all such action as may be required to assure that the Company shall
at all times have authorized and reserved, free from preemptive rights, a sufficient number of shares of the Company’s Common Stock to provide for the exercise by Holder of all its rights with respect to this Warrant. The Company agrees that
its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Company Common Stock upon the exercise of this
Warrant. 
 9. Transfer of Warrant. 

(a) Transferability. This Warrant may not be transferred or assigned in whole or in part without compliance with all applicable federal
and state securities laws by the transferor and the transferee (including the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, if such are requested by the Company). Notwithstanding the
foregoing, no investment representation letter or opinion of counsel shall be required for any transfer of this Warrant (or any portion thereof) or of any shares of the Company’s Common Stock issued upon exercise hereof or conversion thereof
(i) in compliance with Rule 144 or Rule 

  
 5 

 
144A of the Act, or (ii) by gift, will or intestate succession by Holder to his or her spouse or lineal descendants or ancestors or any trust for any of the foregoing; provided that in each
of the foregoing cases the transferee agrees in writing to be subject to the terms of this Warrant. Subject to the provisions of this Warrant with respect to compliance with the Act, title to this Warrant may be transferred by endorsement, in whole
or in part, (by Holder executing the Assignment Form attached hereto as Exhibit B) and delivery in the same manner as a negotiable instrument transferable by endorsement and delivery; provided, however, that in connection with any such transfer any
subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address, and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the
transferee(s) (and Holder if applicable). The Company may refuse to transfer this Warrant or the Warrant Shares to any person who directly competes with the Company, unless, in either case, the stock of the Company is publicly traded. 

(b) Exchange of Warrant Upon a Transfer. Upon surrender of this Warrant for exchange, properly endorsed on the Assignment Form attached
hereto as Exhibit B and subject to the provisions of this Warrant with respect to compliance with the Act and with the limitations on assignments and transfers contained in this Section, the Company at its expense shall issue to, or upon the order
of, Holder a new warrant or warrants of like tenor, in the name of Holder or as Holder (upon payment by Holder of all applicable transfer taxes, if any) may direct, for the number of shares issuable upon exercise hereof. 

(c) Further Compliance with Securities Laws. 

(i) Holder, by acceptance hereof, acknowledges that this Warrant and the Warrant Shares to be issued upon exercise hereof are being acquired
solely for Holder’s own account and not as a nominee for any other party, and for investment, and that Holder will not offer, sell or otherwise dispose of this Warrant or Warrant Shares except under circumstances that will not result in a
violation of the Act or applicable state securities laws. Upon exercise of this Warrant, Holder shall confirm in writing, in a form satisfactory to the Company, that the Warrant Shares so purchased are being acquired solely for Holder’s own
account and not as a nominee for any other party, for investment, and not with a view toward distribution or resale. 
 (ii) This Warrant
and all Warrant Shares issued upon exercise hereof shall be stamped or imprinted with a legend in substantially the following form (in addition to any legend required by applicable state securities laws): 

SECURITIES SUBJECT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND NEITHER THE SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER
SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

  
 6 

 (d) Removal of Legend. The Company agrees to remove promptly, upon the request of the
Holder of this Warrant and securities issuable upon exercise of the Warrant, the foregoing legend from the documents and/or certificates representing such securities upon full compliance with the terms and provisions hereof and Rules 144 and 145
under the Act. 
 (e) Lock-Up Agreement. Holder shall not, without the prior written consent of the Company’s governing body
(such as its Board of Directors) in its sole discretion, offer or sell this Warrant or any of the Warrant Shares for one hundred eighty (180) days after the closing of an initial public stock offering of the Company’s Common Stock under
the Act, the result of which is that the Company’s Common Stock is traded, or quoted, as applicable, on a national securities exchange, over the counter on the Nasdaq Stock Market, or through the National Market System of the Nasdaq Stock
Market (an “IPO”), provided that the Company’s officers, directors and greater than one percent (1%) shareholders are similarly restricted from selling their securities of the Company in that period. 

(f) Registration Under Securities Act of 1933, as amended. The Company agrees that the Warrant Shares shall have certain
incidental or “Piggyback” registration rights pursuant to and as set forth in the Company’s Investors’ Rights Agreement or similar agreement, or if there is no such agreement in existence, then such incidental or
“Piggyback” registration rights as are customary in the venture capital industry. The provisions set forth in the Company’s Investors’ Rights Agreement or similar agreement relating to the above in effect as of the issue date may
not be amended, modified or waived without the prior written consent of Holder unless such amendment, modification, or waiver affects the rights associated with the Warrant Shares in the same manner as such amendment, modification or waiver affects
the rights associated with all other shares of the same series and class as the Warrant Shares granted to Holder. 
 10. University Put Option.
Subject to the terms and conditions of this Section 10, at any time commencing on the date that is sixty (60) days prior to the end of the Exercise Period, University as Holder may notify the Company that University desires to have the
Company repurchase the Warrant at a price equal to the aggregate Fair Market Value of the Warrant Shares minus the aggregate Exercise Price of the Warrant Shares. In the event that, upon the expiration of the Exercise Period, the Fair Market Value
of one share of Common Stock of the Company is greater than the Exercise Price in effect on such date, then regardless of the failure of University to notify the Company of its election pursuant to the preceding sentence, the Company shall
automatically repurchase the Warrant at a price equal to the aggregate Fair Market Value of the Warrant Shares minus the aggregate Exercise Price of the Warrant Shares. The Fair Market Value shall be determined in accordance with Section 3(c),
provided, that if University disputes the Fair Market Value as determined in accordance with Section 3(c), then the Fair Market Value shall be determined by an independent business valuation specialist mutually approved by the Company and
University. Neither the Company nor University shall have had a relationship with such independent business valuation specialist within the immediately preceding three year period. Such determination of the Fair Market Value shall be final and
binding on the Company and University, and the Company shall be obligated to repurchase the Warrant to the extent legally permissible under Delaware law. The Company’s purchase shall be finalized and payment made in cash to University no
later than sixty (60) days after receipt of the Fair Market Value determination. 

  
 7 

 11. Miscellaneous. 

(a) Amendments. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 (b) Governing Law. This
Warrant shall be governed in all respects by the laws of the State of Arizona, without regard to the conflicts of laws provisions thereof. 

(c) Information Rights. So long as the Holder holds this Warrant and/or any of the Warrant Shares, the Company shall deliver to the
Holder (a) promptly after mailing, copies of all communiques to the shareholders of the Company, (b) within one hundred fifty (150) days after the end of each fiscal year of the Company, the annual financial statements of the Company
certified by independent public accountants of recognized standing, if such financial statements have been audited (c) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s
quarterly, unaudited financial statements and (d) within thirty (30) days after the end of each month, a Company-prepared monthly financial statement of the Company. 

(d) Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the
prevailing party shall be entitled to reasonable attorneys’ fees, costs, and disbursements in addition to any other relief to which such party may be entitled. 

(e) Notices. 
 (i)
Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted pursuant to Section 7 hereof, the Company shall, at its expense, compute such adjustment in accordance with the terms of the Warrant and prepare an
accounting setting forth such adjustment showing in detail the facts upon which the adjustment is based including the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Exercise
Price and number of shares purchasable hereunder after giving effect to such adjustment. The Company will mail a copy of each such accounting to the Holder within ten (10) days of such adjustment. 

(ii) In case: 
 1. the Company
shall take a record of holders of its Common Stock (or other stock or securities receivable upon the exercise of this Warrant) for the purpose of entitling them to receive from the Company any dividend or other distribution (whether in cash,
property, stock or other securities and whether or not a regular cash dividend), any right to subscribe for any shares of stock of any class or any other securities (or any stock or securities convertible into capital stock), or to receive any other
right, 
 2. of an offer to sell any shares of the Company’s capital stock (or other securities convertible into such capital stock),
other than (a) pursuant to the Company’s stock option or other compensatory plans, (b) in connection with commercial credit arrangements or equipment financings, or (c) in connection with strategic transactions for purposes other
than capital raising, 
 3. of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any
consolidation or merger of the Company with or into 

  
 8 

 
another corporation (or other business entity), or any conveyance of all or substantially all of the assets of the Company, 

4. of any voluntary or involuntary dissolution, liquidation or winding- up of the Company, or 

5. of any offer to holders of registration rights the opportunity to participate in an underwritten public offering of the Company’s
securities for cash, 
 then in connection with each such event, the Company shall give to Holder: (A) at least fifteen. (15) days prior written
notice of the date on which a record will be taken for dividend, distribution, or subscription rights (and specifying the date on which the holders of Common Stock will be entitled thereto) or for determining the right to vote, if any, in respect of
the matters referred to in (3) and (4) above, (B) in the case of matters referred to in (3) and (4) above, at least fifteen (15) days prior written notice of the date when the same will take place (and specifying the
date on which the holders of Common Stock will be entitled to exchange their Common Stock for securities or other property deliverable upon the occurrence of such event); and (C) in the case of the matter referred to in (5) above, the same
notice as is given to the holders of such registration rights. 
 (iii) Any notice or other communication required or permitted to be given
hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, or by Federal Express, Express Mail or similar overnight delivery or courier service or delivered by facsimile transmission or email or personal delivery
to whom it is to be given, 
 if to the Company: 

President 

High Throughput Genomics 

3430 E. Global Loop 

Tucson, AZ 85706 

if to the University: 

Attn: Case # UA08-033 

Patrick L. Jones, Director 

Office of Technology Transfer 

888 Euclid Ave, Room 204 

P.O. BOX 210158 

Tucson, AZ 85721-0158 
 or in
either case, to such other address or facsimile number as the party shall have furnished in writing in accordance with the provisions of this Section. Notice to the estate of any party shall be sufficient if addressed to the party as provided in
this Section. Any notice or other communication given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party address which shall be deemed given at the time of receipt thereof, Any notice
given by other means permitted by this Section shall be deemed given at the time of receipt thereof. 

  
 9 

 (f) “S” Corporation Covenant. If and for so long as the Company has in effect a
valid election to be treated as an “S” corporation under the Internal Revenue Code, University agrees that it will not: 
 (i)
exercise the Warrant, or 
 (ii) transfer the Warrant to a third party unless that third party agrees in writing: 1) not to exercise this
Warrant if such exercise would cause the Company’s “S” election to be invalid, and 2) not to transfer this Warrant to another party unless that party agrees in writing to be bound by the restrictions set forth in this
Section 11(f)(ii). 
 [Signature Page Follows] 

  
 10 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto
duly authorized. 
  

							
	Dated: March 13, 2009	 		 	HIGH THROUGHPUT GENOMICS, INC.
				
		 		 	By:	 	/s/ Tim B. Johnson
		 		 	Name:	 	Tim B. Johnson
		 		 	Title:	 	President + CEO
			
		 		 	THE ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA
			
		 		 	 /s/ Patrick L. Jones

		 		 	Patrick L. Jones, Director
		 		 	Office of Technology Transfer University of Arizona

  

[Signature Page to Common Stock Warrant] 

 EXHIBIT A 

NOTICE OF EXERCISE 
 To: High
Throughput Genomics, Inc. 
 (1) The undersigned hereby elects to purchase
                     shares of Common Stock of High Throughput Genomics, Inc., a Delaware corporation, pursuant to the terms of
the attached Warrant, and tenders herewith payment of the purchase price for such shares in full. 
 (2) In exercising this Warrant, the
undersigned hereby confirms and acknowledges that the shares of the Company’s Common Stock are being acquired solely for the account of the undersigned and not as a nominee for any other party, for investment, and that the undersigned shall not
offer, sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities Act of 1933, as amended, applicable state securities laws, and that the undersigned will continue to
be bound by Section 9(c) of the Warrant after exercise of this Warrant. 
 (3) Please issue a certificate or certificates representing
such shares of the Company’s Common Stock in the name of the undersigned or in such other name as is specified below: 
  

					
			
	 	  	 	  	  
		  		  	(Name)
			
	 	  		  	 
	 (Date)
	  		  	(Name)

 (4) Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of the
undersigned or in such other name as is specified below: 
  

					
			
	 	  	 	  	  
		  		  	(Name)
			
	 	  		  	 
	 (Date)
	  		  	(Signature)

                     Check here if this Notice is
for a “net exercise” pursuant to Section 3(b) of this Warrant. 

 EXHIBIT B 

ASSIGNMENT FORM 

FOR VALUE RECEIVED, the undersigned registered owner of this Warrant hereby sells, assigns and transfers unto the assignee named below
(“Assignee”) all of the rights of the undersigned under this Warrant, with respect to the number of shares of the Company’s Common Stock set forth below: 

 

					
	 Name of Assignee
	  	Address	  	 No. of

Warrant Shares

		  		  	

  
 and does hereby irrevocably constitute and appoint
Attorney                      to make such transfer on the books of High Throughput Genomics, Inc. maintained for the purpose, with
full power of substitution in the premises. 
 The undersigned also represents that, by assignment hereof, the Assignee acknowledges that
this Warrant and the shares of stock to be issued upon exercise hereof or conversion thereof are being acquired for investment and that the Assignee shall not offer, sell or otherwise dispose of this Warrant or shares of stock to be issued upon
exercise hereof or conversion thereof except under circumstances that will not result in a violation of the Securities Act of 1933, as amended, or applicable state securities laws. Further, the Assignee acknowledges that, upon exercise of this
Warrant, the Assignee shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the shares of stock so purchased are being acquired for investment and not with a view toward distribution or resale. The
Assignee further acknowledges and agrees that it is bound by all of the Warrant, including the provisions of Section 9(c) thereof. 
  

					
			
	  	  	 	  	 
	 (Date)
	  		  	 
		  		  	Signature of Holder
			
		  		  	 
		  		  	Signature of Assignee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]